Furthermore, recent advancements in novel biomarkers (neutrophil gelatinase-associated lipocalin [NGAL], cystatin, calprotectin, and [insulin-like growth factor-binding protein 7] × [tissue inhibitor of metalloproteinase 2]) may provide insights into AKI patient triage, accelerating AKI or acute tubular necrosis (ATN) diagnosis and improving AKI prognosis and RRT prediction [16–22]. This evidence concerns the gene LCN2 and oculocutaneous albinism type 1.